Outcomes and safety analysis of a phase IB trial of stereotactic body radiotherapy (SBRT) to all sites of oligometastatic non-small cell lung cancer combined with durvalumab and tremelimumab.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2021
This article has no abstract
Epistemonikos ID: f5c1fb04c0aefa9c371e5c640c6b64b820e8e3e4
First added on: Feb 13, 2025